Dogwood Therapeutics (NASDAQ:DWTX) Shares Up 1.7% – Time to Buy?

Shares of Dogwood Therapeutics, Inc (NASDAQ:DWTX) were up 1.7% during mid-day trading on Friday . The company traded as high as $3.17 and last traded at $3.06. Approximately 49,806 shares traded hands during trading, an increase of 47% from the average daily volume of 33,985 shares. The stock had previously closed at $3.01.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on DWTX. Wall Street Zen cut Dogwood Therapeutics to a “strong sell” rating in a report on Saturday, December 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dogwood Therapeutics in a report on Monday, December 22nd. Finally, HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Dogwood Therapeutics in a research report on Friday, February 20th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $12.00.

Dogwood Therapeutics Price Performance

The company has a market cap of $98.17 million, a price-to-earnings ratio of -0.12 and a beta of 1.90. The business’s 50-day simple moving average is $3.01 and its 200-day simple moving average is $4.73.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Dogwood Therapeutics stock. Marshall Wace LLP bought a new stake in shares of Dogwood Therapeutics, Inc (NASDAQ:DWTX) during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned about 0.51% of Dogwood Therapeutics as of its most recent filing with the SEC. Hedge funds and other institutional investors own 9.05% of the company’s stock.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.